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Introduction
Hypertension is highly prevalent and one of the most frequent
chronic diseases worldwide.1 It has been suggested that over the
next two decades up to 50% of the adult population will be diagnosed
with hypertension, according to the standard guideline definitions.1
Despite the availability of many safe and effective antihypertensive
drugs, control rates to target blood pressure remain low.2 Approxi-
mately 5–10% of all patients with high blood pressure are resistant to
drug treatment defined as blood pressure.140/90 mmHg,.130–
139/80–85 mmHg in diabetes mellitus or .130/80 mmHg in
chronic kidney disease in the presence of three or more antihyper-
tensives of different classes, including a diuretic, at maximal or the
highest tolerated dose.3 Resistant hypertension is associated with
an increased risk of cardiovascular events.4 Current non-invasive
therapeutic strategies are mainly based on lifestyle interventions
and pharmacological treatment, including mineralocorticoid recep-
tor antagonists.3 Up until recently treatment options for patients
with resistant hypertension were limited. Nowadays catheter-based
renal denervation offers a new approach targeting the renal sympa-
thetic nerves. Indeed, the technique has been shown to reduce sym-
pathetic nerve activity,5 norepinephrine spillover6 as well as blood
pressure7 –9 in patients with resistant hypertension. Several nation-
al10–13 and international14 consensus documents from different so-
cieties have recently been published, with different degrees of
involvement of interventionalists. This expert consensus document
summarizes the view of an expert panel of the European Society of
Cardiology and the European Association of Percutaneous Cardio-
vascular Interventions to provide guidance regarding appropriate
patient selection, efficacy, safety, limitations, and potential new indi-
cations of renal denervation for referring physicians, interventional-
ists, and healthcare providers.
Pathophysiology
The aetiology of resistant hypertension is multi-factorial. However,
there is a large body of evidence indicating the crucial role of the sym-
patheticnervous systemin most typesof hypertensionandnumerous
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cardiovascular diseases, including heart failure, chronic kidney
disease, and the metabolic syndrome.15,16 Afferent and efferent
sensory, chemo- and baroreceptor nerve fibres, form a neural
network within the adventitia of the renal artery (Figure 1).17 Renal
afferent nerves connect the kidney with the hypothalamus, and are
activated by renal ischaemia and high local adenosine concentra-
tions.18 Renal afferent nerve traffic contributes to central sympathet-
ic activity generated in the solitary tract and nucleus. Efferent nerves
innervate the renal vasculature, the tubular segment of the nephron,
and juxtaglomerular renin-containing granular cells, enhancing
sodium and water retention, stimulating renin release, and altering
renal blood flow.16 These effects influence both short- and long-term
blood pressure regulation. Their convenient location in the renal
artery adventitia means that both the efferent and afferent fibres
can now be targeted by catheter-based approaches, thereby
re-setting renal blood pressure regulation. Catheter-based radiofre-
quency ablation has been shown to be as effective as surgical denerv-
ation in terms of reducing kidney norepinephrine content in pigs
(Figure 2).19
The procedure
Numerous new percutaneous renal nerve ablation systems are
currently being tested and will soon be released into the
market. Up to now, five Conformite´ Europe´enne-marked renal
denervation systems using different treatment strategies are avail-
able: Medtronic’s Symplicity system, St. Jude’s EnligHTN system,
Vessix’s V2 system, Covidien’s One Shot system, and Recor’s Para-
dise system (for details, see Table 1). Most of these systems use
radiofrequency energy to target renal sympathetic nerves except
for the ultrasound-based Recor’s Paradise system. The devices
are all inserted percutaneously via a femoral access and advanced
under fluoroscopic control. Beforehand, however, renal artery
anatomical suitability for the procedure should be established,
i.e. a renal artery length is ideally .20 mm with a diameter of
.4 mm. When considering renal nerve ablation, arteries with
visible stenosis, with calcification or atheromatous plaques, repre-
sent relative contraindications. Anectodical reports of renal de-
nervation in arteries with significant stenosis (.50%) or
previous revascularization have been reported, but this off-label
use should be avoided. Recently published data indicated that
the applied radiofrequency energy resulted in transient local
de-endothelialization, acute cellular swelling, connective tissue co-
agulation, and thrombus formation.20 Although controlled data are
lacking, these observations suggest that the use of antiplatelet
therapy during the procedure (acetylsalicylic acid 250 mg i.v.)
and for up to 4 weeks after renal denervation (75–100 mg/day
p.o.) might be advisable.
Owing to the co-location of sympathetic nerves and C pain fibres,
analgesia and sedation (e.g. using midazolam, morphine, remifenta-
nile, fentanyl, or propofol) is mandatory during radiofrequency abla-
tion. The presence of an anaesthesiologist is not generally necessary,
however, in some countries required. During the procedure vital
signs (including blood pressure, heart rate, and oxygen saturation)
need to be monitored. In some patients, radiofrequency ablation
may causes renal artery oedema and/or spasm at the treatment
sites, which can be treated by using intra-arterial nitroglycerine or
verapamil. Even when vascular spasm is persistent during the proced-
ure despite these treatments it typically disappears within hours after
the ablation. The procedural time normally ranges from 45 to 60 min.
Numerous new catheter systems and treatment modalities for
renal denervation are under development. The products include
new radiofrequency catheters, but also novel treatment modalities
using catheter-based ultrasound energy, cryoablation techniques,
Figure 1 Efferent and afferent renal sympathetic nerves (modified with permission from Lu¨scher, PCR-EAPCI Textbook). HR, heart rate; RBF,
renal blood flow; GFR, glomerular filtration rate.
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radiation, local drug-delivery, or even external application of ultra-
sound energy. It is important to note that all the new devices pre-
sented above and especially those using new treatment modalities
such as ultrasound or chemical denervation will have to show favour-
able safety and efficacy profiles in a larger cohort of patients with sub-
sequent long-term follow-up before a general use can be
recommended.21
Clinical trials
Efficacy
The initial proof-of-concept study Symplicity HTN-16 and the
multi-centre, prospective, randomized Symplicity HTN-2 trial7
investigated the effect of renal denervation in 45 and 106 patients
with resistant hypertension, respectively. Baseline blood pressure
was 177/100 and 178/96 mmHg, respectively, despite treatment
with four or more antihypertensive drugs on average. Renal denerv-
ation resulted in significant systolic and diastolic blood pressure
reductions that were first observed at 1 month (214/210 mmHg,
P ¼ 0.026) and persisted out to 24 months (232/214 mmHg, P ¼
0.001).8 The presented 36-month long-term follow-up of this
non-randomized small study confirmed a sustained blood
pressure-lowering effect of 33 and 19 mmHg (P, 0.01, n ¼ 34).22
Self-measured home blood pressure assessed in a subgroup of 32
patients decreased by 20/12 mmHg (P, 0.0001), compared with
2/0 mmHg in 40 control patients. As expected, the reduction in
ambulatory blood pressure monitoring over 24 h after renal denerv-
ation was smaller compared with the observed changes in office-
based blood pressure (i.e. 11/7 mmHg; P ¼ 0.007, n ¼ 20). The
response to treatment was defined as a reduction in systolic blood
pressure (SBP) .10 mmHg at 6-month follow-up and was found in
84% of patients.
It is important to note that blood pressure rarely changes immedi-
ately after the procedure. It often takes several weeks to months
before a notable blood pressure reduction occurs, suggesting that
a slowly progressive resetting of sympathetic neural regulation
occurs. Patients and treating physicians should therefore be informed
to avoid unrealistic expectations in the immediate aftermath of the
procedure. Furthermore, it is important to communicate to patients
and referring physicians that renal denervation as currently deployed
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Figure 2 Tissue norepinephrine content in untreated controls
and pigs undergoing catheter-based renal denervation and surgical
denervation (modified from19).
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is designed to improve blood pressure control in patients whose
blood pressure is resistant to control with conventional drug
therapy. In this regard, renal denervation is unlikely to significantly
reduce pill burden in most patients and is not a cure for hypertension.
Neither in the Symplicity HTN-1 nor in the HTN-2 a reduction in
antihypertensive background medication has been investigated as
an endpoint. Of note, both studies have been sponsored by the man-
ufactures of the renal denervation device (Ardian/Medtronic).
Safety
In the Simplicity trials, the treatment was performed without major
complications in 98% (201 of 209) of the cases included.6 –8 The fol-
lowing complicationshave been reported: three femoral artery pseu-
doaneurysms, one urinary tract infection, one case of back pain, one
extended hospitalization for assessment of paresthaesia, and one
renal artery dissection during placement of the guiding catheter.
Vasovagal reactions occurred in seven patients (13%) during the
intervention, which resolved under treatment with atropine. Six-
month renal vascular imaging in 130 patients who underwent renal
denervation identified one patient with possible progression of an
underlying atherosclerotic lesion, which required no therapy. Two
case reports have been published describing a secondary rise in
blood pressure after renal denervation caused by a progression of
a renal artery stenosis.24,25 It remains unanswered to which extent
the ablation procedure and/or the catheter manipulation induced
or promoted the rapid development of renal artery stenosis or
whether it represented a natural progression of the disease process.
Concerns have been raised that renal denervation might negatively
influence renal function.26 In the Symplicity HTN-1 trial with an
extended follow-up of 24 months in 64 patients, estimated glomeru-
lar filtration rate (eGFR) (measured by modification of diet in renal
disease) remained stable during the first year of follow-up, whereas
eGFR data of the 2-year follow-up is currently available only in 10
patients.8 In these 10 patients, eGFR was reduced by 16 mL/min/
1.73 m2, which was thought to be related to changes in diuretic
therapy. The effect of renal denervation on renal function and
urinary albumin excretion has been investigated in 100 patients
with resistant hypertension and preserved renal function.27 The
study demonstrated a reduced number of patients with micro- and
macroalbuminuria after renal denervation, without adversely affect-
ing glomerular filtration rate (GFR) or renal artery structure within
6 months. It is important to note that, in the Symplicity trials, patients
with an eGFR of,45 mL/min/1.73 m2 were excluded as a matter of
safety. Although preliminary data suggest that renal denervation is
also safe and effective in patients with moderate-to-severe chronic
kidney disease,28 these patients should only be treated in clinical
studies with subsequent follow-ups.
The effect of renal denervation on the physiological response
during cardiopulmonary exercise testing has been tested.29 Renal de-
nervation resulted in a significant drop in resting, maximum exercise,
and recoveryblood pressure, whereas heart rate response during ex-
ercise and oxygen uptake was well preserved.
Anotherconcernhasbeen the occurrence oforthostatic hypoten-
sion after renal nerve ablation as it has occurred in the 1950’s with
surgical sympathectomy for severe hypertension.30 Fortunately,
such a side-effect does not seem to occur with catheter-based
renal denervation; indeed, a recent study investigated blood pressure
changes upon changes in posture without evidence for an alteration
in the orthostatic response after the procedure.31
Limitations
One of the major challenges is how to monitor the success of the
procedure. There are no easily deployed tests to determine
whether the denervation procedure has been wholly or partially ef-
fective or ineffective. Furthermore, not all patients respond to treat-
ment with blood pressure lowering. Is this because there is a
hypertensive phenotype that is destined not to respond to the pro-
cedure or, that the procedure has not been deployed effectively in
these patients? Thus, parameters predicting the likelihood of re-
sponse and the overall success of the renal denervation procedure
are lacking. However, as in trials of antihypertensive drugs, SBP at
baseline has been identified as one predictor of the magnitude of
the BP-lowering response,27 which might be at least in part explained
by the statistical phenomenon of ‘regression to the mean’. In Sympli-
city HTN-2,7 an intake of centrally acting sympatholytics was identi-
fied as a predictor of pronounced blood pressure response, which is
surprising because one might have expected drugs targeting the same
mechanism as renal denervation to be more effective. At present, no
negative blood pressure predictors have been identified and as noted
above there areno reliablebiochemical orother parameters, suitable
for everyday clinical practice, for assessing the success of renal de-
nervation or the degree of renal denervation achieved.
The exact mechanisms by which renal denervation results in a
blood pressure reduction are not yet fully established, but are likely
to include a reduction in total peripheral resistance, reduced renin
release, and favourable alterations of water and salt handling. Of
note, measurements of sympathetic nerve traffic in the peroneal
nerverevealed that sympathetic activity is also reduced after renalde-
nervation.5 This is important because it suggests that whole-body
sympathetic nerve activity is reduced following the procedure,
most likely due to reduced afferent central nervous system input
directing a reduction in central sympathetic outflow.5 However,
one published study reported in a small group of 12 patients no sig-
nificant overall blood pressure-lowering effect and no changes in
muscle sympathetic nerve activity after renal denervation (RDN).32
The interpretation of this study is limited to the fact that, in contrast
to the Symplicity trials, the baseline BP was only 157/85 mmHg
(thereby ≈20/10 mmHg lower) and some of the subjects had
non-treatment-resistant hypertension (42% of the patients had SBP
≤140 mmHg).33 Thus, lower blood pressure responses had to be
expected although sympathetic activation is present even in mild
forms of hypertension.34 Differently, in a larger case-controlled
series of patients, all with confirmed multi-drug-resistant hyperten-
sion and elevated blood pressure report a mild reduction of multi-
unit muscle sympathetic nerve activity (MSNA) and a significant re-
duction in single-fibre MSNA was reported.5 The series differ in
both entry blood pressure and multi-unit MSNA bursts/100 heart
beats, and underlying pharmaceutical use.
Whether the effects of renal denervation will be sustained beyond
the time span currently documented (36 months)22 is uncertain.
Indeed, animal studies and transplant experiments have demon-
strated that sympathetic renal nerves have the capacity to re-grow
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and/or regenerate over time.35– 37 Therefore, the long-term efficacy
of the procedure still remains an important question, because only
limited information about the long-term follow-up of patients is avail-
able, both in clinical trails and in real-life setting. The available
36-month follow-up data of the Symplicity HTN-1 trial22 are encour-
aging as they show a sustained blood pressure-lowering effect, sug-
gesting a significant and functionally relevant regrowth of the renal
nerves is unlikely. The question whether a repeated intervention
with RDN could be performed in patients with inadequate response
to a first procedure has been raised. However, with present knowl-
edge, this could not be recommended.
Only limited information about the impact of renal denervation on
daytime, night-time, and average blood pressure is available from the
Symplicity HTN-2 trial7 and from that data it has been argued that
renal denervation might not reduce ambulatory blood pressure
equally as effectively as office blood pressure.26 A multi-centre ana-
lysis of more than 300 patients undergoing renal denervation has sub-
sequently shown that the procedure significantly reduces office and
24 h average, daytime, and night-time blood pressure in patients with
resistant hypertension and increases the percentage of patients con-
trolled to target blood pressure values, both according to office
blood pressure and ambulatory blood pressure monitoring
(Mahfoud F, Homburg/Saar, data on file).
In contrast to some antihypertensive drug regimen, renal denerv-
ationhasnotbeen shown toaffect cardiovascular morbidityandmor-
tality. Although outcome improvement is very likely, when a strong
blood pressure reduction is accepted as a valid outcome surrogate
in severe and resistant hypertension, this clearly represents an
unmet need and has to be investigated in future trials to definitely de-
termine the role of this device-based therapy. The multi-centre, pro-
spective, single-blinded, randomized, placebo-controlled Symplicity
HTN-3 study (NCT01418261) is recruiting patients in the USA,
which will hopefully answer the question of whether a contributing
placebo effect imposes bias on the results of renal denervation.
Patient selection
According to the available evidence,6– 8 patients are eligible for
renal denervation if they have (severe) treatment-resistant hyper-
tension defined by office SBP ≥160 mmHg (≥150 mmHg in type
2 diabetes) despite treatment with at least three antihypertensive
drugs of different types in adequate doses, including one diuretic.
In certain centres, uncontrolled blood pressure values .140/
90 mmHg are taken as reference. High office blood pressures
should be confirmed by ambulatory blood pressure monitoring
and pseudo-resistance has to be excluded. Pseudo-resistant hyper-
tension should be considered particularly in patients whose clinical
blood pressure is consistently higher than out-of-office measure-
ments (mean daytime BP, 135 mmHg).38 Before a patient with
uncontrolled hypertension is considered for renal denervation,
patients should have been evaluated by a hypertension expert
in specialized centres (e.g. Hypertension Excellence Centers;
see http://www.eshonline.org/Communities/CentresList.aspx).
Optimization of antihypertensive drug treatment and identification
of contributing lifestyle factors should be part of the work-up.
Special emphasis should be put on the potential additional advan-
tages of the treatment with mineralocorticoid receptor antagonists
(i.e. spironolactone, eplerenone), which may be particularly effect-
ive in patients with resistant hypertension.39 However, concerns
have been raised about the long-term safety of these drugs espe-
cially in patients with reduced renal function and already existing
blockade of the renin–angiotensin system.14 Therefore, a general
recommendation that only patients in whom treatment with min-
eralocorticoid receptor antagonists has failed, should be consid-
ered for renal denervation, cannot be sustained. Secondary
hypertension, including renal artery stenosis, pheochromocytoma,
sleep apnoea syndrome, and primary hyperaldosteronism, must be
systematically ruled out. Figure 3 summarizes the recommended
screening process before a patient is considered for renal denerv-
ation. Based on the exclusion criteria of the Symplicity trials,6– 8
the following criteria should also be implemented in order to
safely proceed to renal denervation: previous renal artery inter-
vention (balloon angioplasty or stenting), evidence of renal
artery atherosclerosis (defined as a renal artery stenosis .50%),
presence of multiple main renal arteries in either kidneys or
main renal arteries of ,4 mm in diameter or ,20 mm in
Figure 3 Appropriate screening is mandatory to select the right
patients (modified from57).
Table 2 Criteria patients should comply with before
renal denervation is considered
† Office-based systolic BP ≥ 160 mmHg (≥150 mmHg diabetes
type 2)
† ≥3 antihypertensive drugs in adequate dosage and combination
(incl. diuretic)
† Lifestyle modification
† Exclusion of secondary hypertension
† Exclusion of pseudo-resistance using ABPM (average
BP. 130 mmHg or mean daytime BP. 135 mmHg)
† Preserved renal function (GFR ≥45 ml/min/1.73 m2)
† Eligible renal arteries: no polar or accessory arteries, no renal artery
stenosis, no prior revascularization
BP, blood pressure; ABPM, ambulatory blood pressure monitoring; GFR, glomerular
filtration rate.
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length. The kidney function should be preserved (GFR ≥45 mL/
min per 1.73 m2), although renal denervation seems to be safe
and effective also in patients with moderate-to-severe chronic
kidney disease.28 Table 2 summarizes the criteria for renal denerv-
ation according to the currently available clinical evidence. It
should also be considered that patients presenting with resistant
hypertension often report adverse effects of antihypertensive
therapy. So far, no study has been published to investigate the
effect of renal denervation in patients intolerant to various
drugs, although this can be a relevant problem. Therefore, no
general recommendation can be given at this time. However, in
patients with reproducible drug intolerance or significant adverse
effects an individualized decision-making process appears to be
reasonable.
Centre selection
In patients with uncontrolled hypertension, secondary causes of
hypertension are common. Therefore, a detailed screening process
is mandatory to identify patients with potentially curable forms of
hypertension, since renal denervation is not an effective therapy in
these patients. Centres should be specialized in the management of
hypertension (e.g. Hypertension Excellence Centers, see http
://www.eshonline.org/Communities/CentresList.aspx), with at least
one hypertension expert being actively involved in the treatment
and screening process. In order to avoid high complication rates, it
is recommended that the interventions are performed by interven-
tional cardiologists or angiologists who have been trained in perform-
ing this specific intervention and who are qualified to manage
potential complications, such as acute dissection of renal arteries
by stent implantation. Appropriate expertise could be assumed in
centres with .25 renal interventions per year. At this stage of the
introduction of the procedure, centres should enter their data into
large registries to ensure proper quality control and to allow for an
analysis of the procedural success acutely and at long-term follow-up.
Table 3 provides suggested follow-up examinations after renal de-
nervation.
Cost-effectiveness
The cost-effectiveness and long-term clinical benefits of renal de-
nervation in patients with resistant hypertension have recently
been published,40 using a state-transition (Markov) model. The
results indicate that renal denervation, although the treatment repre-
sents an additional cost at the time of the procedure (hospitalization,
catheter, and operator costs), appears to offer a great value over time
andmight becost-effectivewhencomparedwith othermedical treat-
ments. The estimated incremental lifetime cost-effectiveness ratio
was $3071 per quality-adjusted life-year and thereby below the com-
monly accepted threshold of $5000. Predicted median survival was
18.4 years for renal denervation and 17.1 years for standard of
care. However, these assumptions will be sensitive to costs in differ-
ent healthcare systems and are based on the assumption that blood
pressure-lowering drugs or denervation offer no value or harm
beyond their impact on blood pressure lowering.
Potential beneficial effects beyond
blood pressure lowering
Diabetes mellitus and insulin resistance
Activation of the sympathetic nervous system is a main contributor to
insulin resistance, metabolic syndrome, associated with central
obesity, and risk of developing diabetes.41,42 A bidirectional relation-
ship between sympathetic overactivity inducing insulin resistance and
hyperinsulinemia producing sympathetic activation exists. In a pilot
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Suggested follow-up examinations after renal denervation
Baseline 3 months 6 months 12 months 24 months 36 months 48 months 60 months
Office BP X X X X X X X X
ABPM X X X X X X X X
Heart rate X X X X X X X X
Body weight X X X X X X X X
Review medications X X X X X X X X
Blood tests, including GFR
determination
X X X X X X X X
ECG X X X X X X X
Renal artery imaging (duplex
ultrasound, MRI/CT with contrast
or angiogram)
X X X X X X X
Oral glucose tolerance test (where
appropriate)
X X X X X X X
Echocardiography in patients with
heart failure or left ventricular
hypertrophy
X X X X X X X
UACR in patients with albuminuria X X X X X X X X
BP, blood pressure; ABPM, ambulatory blood pressure monitoring; ECG, electrocardiogram; UACR, urine albumin to creatinine ratio.
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study43 renal denervation positively influenced glucose metabolism
in patients with resistant hypertension. Three months after the pro-
cedure fasting glucose, fasting insulin and 2 h glucose concentration
during oral glucose tolerance testing were significantly reduced
resulting in a significant improvement of insulin sensitivity (measured
using the HOMA index), whereas there were no changes in the
control group. Similar findings have been reported from a study,44
investigating the effect of renal denervation in patients with obstruct-
ive sleep apnoea. Beside reductions in the severity of obstructive
sleep apnoea, the authors report changes in 2 h glucose concentra-
tion during oral glucose tolerance test and reductions in HbA1c. A
preliminary report in two patients with polycystic ovary syndrome45
suggests that renal denervation lowers blood pressure and improves
insulin resistance (measured by euglycemic clamp technique) in the
absence of changes in body weight over a 3 month period. Further
trials are necessary to document the durability of these results
as well as their implications for the management of patients with
diabetes.
Cardiac effects
Neurohumoral activation, in particular activation of the sympathet-
ic nervous system, is of prognostic relevance in patients with
chronic heart failure and antagonism of the sympathetic system
with beta-blockers significantly reduces cardiovascular morbidity
and mortality.46 The kidneys have been identified as a main con-
tributor to the complex pathophysiology, formally called cardio-
renal syndrome.47 One published study48 investigated the effects
of renal denervation on left ventricular mass and diastolic filling
pattern in 46 patients with resistant hypertension in which renal
denervation was associated with substantial reductions in blood
pressure and significantly reduced left ventricular mass and mean
interventricular septum thickness. Diastolic function (as assessed
by mitral valve lateral E/E′) was improved after renal denervation
and there was a reduction of left ventricular filling pressures and
improvement in ejection fraction. In a small first-in man pilot
study, involving seven normotensive patients with chronic heart
failure, 6 months after renal denervation, their 6 min walk distance
improved significantly and the patients’ self-assessment of well-
being also improved.49 There were no significant changes in
blood pressure, renal function, and no symptomatic fluctuations
in haemodynamics. A randomized, controlled multi-centre trial
(RE-ADAPT-CHF) investigating the effects of renal denervation
in 100 patients with chronic heart failure (NYHA functional class
II– III) is currently underway and will provide important
information.
Chronic kidney disease
Abundant evidence shows that chronic kidney disease is character-
ized by sympathetic activation, contributing to hypertension and
the progressive loss of renal function.50 Renal denervation could
therefore be a potentially novel therapeutic strategy in patients
with impaired renal function, including end-stage kidney disease.
However, in the Symplicity HTN trials, patients with GFR ,45 mL/
min/1.73 m2 were excluded, thus, because the safety of such an inter-
vention in this patient population is uncertain. Recently, the effects of
renal denervation in a small series of 15 patients with moderate-to-
severe chronic kidney disease (mean GFR 31 mL/min/1.73 m2)
were reported.28 Renal denervation was effective in terms of blood
pressure lowering and there was no evidence of a further decline in
GFR or effective renal plasma flow 6 months after the procedure,
despite exposure to contrast medium. Owing to the limited data,
however, patients with higher grades of renal insufficiency should
only be treated in the context of clinical research studies.
Antiarrhythmic effects
The autonomic nervous system also modulates cardiac electro-
physiology properties including chronotropy and dromotropy, de-
polarization rate of the sinus node, and atrioventricular
conduction.51 Renal denervation has been shown to significantly
reduce the resting heart rate in patients with resistant hyperten-
sion and prolonged PR interval.52 Interestingly, neither baseline
heart rate nor changes in heart rate correlated with the blood
pressure reductions. In a first-in-human experience renal denerv-
ation was used as bailout therapy in two patients with congestive
heart failure suffering from treatment-resistant electrical storm.53
Following renal denervation, ventricular tachyarrhythmias were
significantly reduced in both patients. The impact of renal denerv-
ation in patients with refractory atrial fibrillation and resistant
hypertension has been assessed in a study.54 Twenty-seven
patients were randomized to pulmonary vein isolation alone or
pulmonary vein isolation plus renal denervation. Besides significant
reductions in blood pressure, patients in the pulmonary vein isola-
tion plus renal denervation group experienced significantly fewer
episodes of atrial fibrillation at follow-up. Furthermore, animal
experiments support the antiarrhythmic effects of renal denerv-
ation and suggest a reduced inducibility of atrial fibrillation after
the procedure.55 Thus, the role of renal denervation in the field
of arrhythmias deserves further exploration in well-defined re-
search protocols. However, due to the limited number of patients
investigated so far, a routine use cannot be recommended.
Hypertensive end-organ damage
It has been shown that pulse wave reflection and augmented pulse
wave velocity representing vascular stiffness are adversely related
to cardiovascular morbidity and mortality in patients with hyperten-
sion. Renal denervation significantly reduced central pulse pressure,
associated with peripheral pulse pressure, and resulted in a reduction
of pulse wave velocity indicating vascular peripheral re-remodelling
effects.56 This was especially documented in patients with high vascu-
lar stiffness at baseline. Albuminuria has been extensively investigated
to be a signof early renal damage in hypertension and can be regarded
as hypertensive end-organ damage. It has been shown that renal de-
nervation could reduce the number of patients with macroalbumi-
nuria and microalbuminuria to lower grades of urinary albumin
excretion resulting in a higher portion of individuals without micro-
or macroalbuminuria during follow-up of 6 months.27
Summary
Current evidence from the available clinical trials strongly support
the notion that catheter-based radiofrequency ablation of renal
nerves reduces blood pressure and improves blood pressure
control in patients with drug-treated resistant hypertension, with
data now extending out to 36 months. Accordingly, renal
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denervation can be considered as a therapeutic option in patients
with resistant hypertension, whose blood pressure cannot be con-
trolled by a combination of lifestyle modification and pharmacologic-
al therapy according to current guidelines. The fact that renal
denervation also reduces whole-bodysympathetic nerve activity sug-
gests that this therapy may also be beneficial in other clinical states
characterized by sympathetic nervous system activation—this may
ultimately lead to new indications.
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